homepage-top-section

Expected to be funded using nearly $35m of cash and cash equivalents at closing, the combined company will focus on advancing CalciMedica’s pipeline of first-in-class product candidates. The

SDX is the company’s proprietary prodrug of d-methylphenidate (d-MPH) and is the sole active pharmaceutical ingredient (API) in its lead clinical candidate KP1077. KP1077 is being developed for

As per the terms of the agreement, Tenacia will get sole rights to develop and commercialise some formulations of ganaxolone in Mainland China, Hong Kong, Macau and Taiwan,

The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces

This approval comes after European Commission gave its approval earlier this month. About 90% of children by the age of two get infected by RSV, which is a

The new 1,500m2 facility will expand the company’s large-scale viral vectors production capabilities for vaccines and gene therapy. It has been designed to meet the increasing demand for

Brukinsa has been approved to treat relapsed/refractory (R/R) MZL adult patients who have previously received at least one anti-CD20-based therapy. The Bruton’s tyrosine kinase (BTK) small molecule inhibitor,

Under the deal terms, the company obtained an exclusive option for evaluating the regulatory, clinical development and commercialisation plan for CWRU’s intellectual property portfolio for up to 12

Under the collaboration, the company will be responsible for the vaccine epitope selection portion using its in silico vaccine design toolkit, iVAX. EpiVax will work as a subgrantee